Short Interest in Apollomics Inc. (NASDAQ:APLM) Decreases By 51.2%
by Teresa Graham · The Cerbat GemApollomics Inc. (NASDAQ:APLM – Get Free Report) was the target of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 1,592 shares, a drop of 51.2% from the May 14th total of 3,260 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 10,971 shares, the short-interest ratio is currently 0.1 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
View Our Latest Report on APLM
Apollomics Price Performance
Shares of APLM stock traded up $0.13 on Friday, reaching $13.83. 15,864 shares of the company’s stock were exchanged, compared to its average volume of 10,241. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12. The company’s fifty day simple moving average is $14.27 and its 200 day simple moving average is $17.17.
Institutional Investors Weigh In On Apollomics
A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new position in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. 19.13% of the stock is currently owned by institutional investors.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.